{"disease":{"id":"squamous-cell-lung-carcinoma","name":"squamous cell lung carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03199651","title":"Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":3584,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02154490","title":"Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1864,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT00946712","title":"S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1333,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07147361","title":"Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06494540","title":"NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02193282","title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":390,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07070518","title":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"GV20 Therapeutics","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04181060","title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04429542","title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":292,"lead_sponsor_name":"Bicara Therapeutics","has_results":false},{"nct_id":"NCT02785952","title":"Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":275,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT03829501","title":"A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":222,"lead_sponsor_name":"Kymab Limited","has_results":true},{"nct_id":"NCT04032704","title":"A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":205,"lead_sponsor_name":"Seagen Inc.","has_results":true},{"nct_id":"NCT03752398","title":"A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT05551117","title":"A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":192,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT04802876","title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"SOLTI Breast Cancer Research Group","has_results":false},{"nct_id":"NCT04242199","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT07169734","title":"A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Alentis Therapeutics AG","has_results":false},{"nct_id":"NCT06747585","title":"A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Alentis Therapeutics AG","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT07217171","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"EvolveImmune United, Inc","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT03110978","title":"Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06047379","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Neonc Technologies, Inc.","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02245100","title":"Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT04310007","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":117,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04357873","title":"Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT04272034","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":105,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03509012","title":"Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04152018","title":"Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":85,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03621982","title":"Study of ADCT-301 in Patients With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"ADC Therapeutics S.A.","has_results":true},{"nct_id":"NCT03849469","title":"A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT04916002","title":"A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":77,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT04260802","title":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"Ocellaris Pharma, Inc.","has_results":false},{"nct_id":"NCT06147037","title":"A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05403554","title":"A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Light Chain Bioscience - Novimmune SA","has_results":false},{"nct_id":"NCT03373760","title":"Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT02276027","title":"A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03845296","title":"Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT03195699","title":"Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Tvardi Therapeutics, Incorporated","has_results":false},{"nct_id":"NCT04060342","title":"GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":61,"lead_sponsor_name":"GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.","has_results":false},{"nct_id":"NCT02495896","title":"Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT06444815","title":"A Study of VET3-TGI in Patients With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"KaliVir Immunotherapeutics","has_results":false},{"nct_id":"NCT05585034","title":"Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT01386385","title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":53,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03377556","title":"Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}